Audiological monitoring in Swiss childhood cancer patients

Weiß, Annette; Kuonen, Rahel; Brockmeier, Hanna; Grotzer, Michael A.; Candreia, Claudia; Maire, Richard; Senn, Pascal; Stieger, Christof; Rosenfeld, Jochen; Veraguth, Dorothe; Kompis, Martin; Scheinemann, Katrin; Kuehni, Claudia E.

doi:10.1002/pbc.26877

Cited by 13 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It might be explained by the fact that they frequently suffer from reduced neurocognitive functioning and sometimes have to repeat a year in school. [29] Since audiological monitoring is only partly implemented for survivors in Switzerland [8], health professionals should pay careful attention to hearing problems and their effects in survivors of CNS tumours. Future studies should investigate if hearing aids or other interventions, including speech therapy, frequency modulation amplification systems or preferential classroom seating, help reducing problems with peers.…”

Section: Discussionmentioning

confidence: 99%

“…While hearing loss can pose difficulties for any child, survivors treated for central nervous system (CNS) tumours may suffer more from hearing loss since they often have multiple late effects which may reduce their social and educational skills [5]. Recently, oncologists have become more aware of ototoxicity [6][7][8]. Survivors should be carefully monitored for audiological problems and offered timely and targeted interventions to help them cope with hearing loss [9].…”

Section: Introductionmentioning

confidence: 99%

“…Survivors should be carefully monitored for audiological problems and offered timely and targeted interventions to help them cope with hearing loss [9]. Audiological monitoring has not yet been fully implemented for survivors in follow-up care in Switzerland [8] and there is, currently, little data on the effects of hearing loss on childhood cancer survivors.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers

et al. 2018

Self Cite

View full text Add to dashboard Cite

Hearing loss, a complication of cancer treatment, may reduce health-related quality of life (HRQoL), especially in childhood cancer survivors of central nervous system (CNS) tumours who often have multiple late effects. We examined the effect of hearing loss on HRQoL in young survivors of CNS and other childhood cancers. Methods: Within the Swiss Childhood Cancer Survivor Study, we sent questionnaires about hearing loss and HRQoL (KIDSCREEN-27) to parents of survivors aged 8-15 years. We stratified the effect of hearing loss on HRQoL by cancer diagnosis, using multivariable logistic regression and adjusting for sociodemographic and clinical factors. Results: Hearing loss was associated with impaired physical well-being [unadjusted estimated differences -4.6 (CI -9.2; -0.1); adjusted -4.0 (CI -7.6; -0.3)] and peers & social support [unadjusted -6.7 (CI -13.0; -0.3); adjusted -5.0 (CI -10.5; 0.9)] scores in survivors of CNS tumours (n=123), but not in children diagnosed with other tumours (all p-values > 0.20, n=577). Conclusion:Clinicians should be alert to signs of reduced physical well-being and impaired relationships with peers. Especially survivors of CNS tumours may benefit most from strict audiological monitoring and timely intervention to mitigate secondary consequences of hearing loss on HRQoL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…4,5,11 This is important because hearing deficits may adversely affect speech and language, social-emotional development, and academic performance in children. 12,13 Recent population-based surveys suggest that despite recommendations, monitoring of hearing loss in survivors is insufficient at the population level, with only 72% of those at risk having hearing tests during follow-up, and only 43% having full audiological monitoring (before, during, and after treatment) 14 . Therefore, clinical practice guidelines are needed to facilitate timely identification of and intervention for ototoxicity among at-risk CAYA cancer patients and survivors after completion of therapy.…”

Section: Introductionmentioning

confidence: 99%

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Clemens

Heuvel‐Eibrink

Mulder

et al. 2019

The Lancet Oncology

Self Cite

View full text Add to dashboard Cite

“…Currently, the International Late Effects of Childhood Cancer Guideline Harmonization Group is developing recommendations for audiological monitoring in CCS. The guideline unifies existing recommendations and provides optimum follow-up practices, which is important for consensus on the frequency and timing of audiological evaluations after childhood cancer [59].…”

Section: Discussionmentioning

confidence: 99%

Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study

Clemens¹,

Meijer²,

Broer³

et al. 2019

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However, results were inconsistent and most studies were underpowered and/or lacked replication. Objective We describe the design of the PanCareLIFE consortium’s work packages that address the genetic susceptibility of platinum-induced ototoxicity. Methods As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a candidate gene approach and a genome-wide association screening. Results This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer, resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided, for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses and the first results are expected by the end of 2019 or the beginning of 2020. Conclusions Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies. International Registered Report Identifier (IRRID) DERR1-10.2196/11868

show abstract

Audiological monitoring in Swiss childhood cancer patients

Abstract: Our population-based study indicates that audiological monitoring is insufficient in Switzerland, particularly for nonstudy patients. Clinicians must become more aware of the importance of full audiological monitoring.

Cited by 13 publications

References 24 publications

Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers

Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study

Contact Info

Product

Resources

About